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Modulation of T Cell Cytokine Profiles and Peptide-MHC
Complex Availability In Vivo by Delivery to Scavenger
Receptors via Antigen Maleylation1
Nagendra Singh,2 Sumeena Bhatia, Roshini Abraham,3 Sandip K. Basu, Anna George,
Vineeta Bal, and Satyajit Rath4
We have previously shown that conversion of proteins to scavenger receptor (SR) ligands by maleylation increases their immu-
nogenicity. We now show that maleyl-Ag-immune spleen cells make relatively more IFN-g and less IL-4 or IL-10 than native
Ag-immune cells. This is also reflected in the IgG1:IgG2a ratios in Abs generated in vivo. SR engagement on macrophages does
not alter their surface levels of the adhesive/costimulatory molecules CD11a/CD18, CD11b/CD18, CD24, CD54, or CD40, nor does
it enhance their ability to support anti-CD3-driven proliferation of naive T cells in vitro. Costimulatory molecules implicated in
differential Th1/Th2 commitment—CD80, CD86, and IL-12—are not inducible by SR ligation. In addition to macrophages and
dendritic cells, B cells also show receptor-mediated uptake and enhanced presentation of maleyl-Ags. Using a monoclonal T cell
line to detect peptide-MHC complexes expressed on spleen cells in Ag-injected mice, we find that higher levels of these complexes
are generated in vivo from maleyl-proteins and they persist longer than those generated from the native protein. Together, these
data suggest that in certain situations, the levels of cognate ligand available and/or the time course of their availability may play
a major role in determining the cytokine profiles of the responding T cells in addition to the costimulatory signals implicated so
far. The Journal of Immunology, 1998, 160: 4869–4880.
G eneration of a successful T cell response involves cog-nate interaction of TCR with appropriate peptide-MHCcomplexes on the APC surface as well as the delivery of
costimulatory signals from APCs. Differing immune effector path-
ways of T cells may be optimally useful for different kinds of
infections. Data from many experimental systems suggest that
CD4 T cells can enter one of two effector pathways, commonly
called the Th1 and the Th2 cell pathways, characterized by differ-
ing cytokine packages (1, 2). Th1 T cells appear to generate mainly
IFN-g and TNF-b, contribute to the generation of inflammation
(3), and are needed to eliminate facultative intracellular parasites
such as Leishmania (4), while Th2 T cells make IL-4, IL-5, and IL-10
and help in the generation of IgG1 and IgE Ab responses (2, 5).
The complex mechanisms regulating triggering of Th1 or Th2
responses are the subject of much interest, and many investigations
have focused on the differential roles played by different APC
types (6, 7). Th1 T cell clones are better stimulated in vitro by
macrophages as APCs rather than by B cells, while the reverse is
true for Th2 clones (8). Targeting Ags to small B cells in vivo, on
the other hand, may lead to T cell tolerance rather than activation
(9), although recent reports suggest that the involvement of B cells
in Ag presentation during T cell priming may bias the T cells
toward a Th2 phenotype (10). There are data linking differential
production of cytokines such as IL-12 (11) and IL-4 (12) early in
the course of the immune response to the qualitative outcome of
the immune response, and cell types differ in their abilities to con-
tribute such cytokines (13, 14). Differential expression of costimu-
latory molecules such as CD80 and CD86 has also been implicated
in the preferential induction of Th1 vs Th2 responses (15, 16). The
other factor argued to be involved in regulating commitment to
Th1/Th2 phenotypes is the ligand density of the cognate peptide-
MHC signal. Peptides with a high affinity for MHC class II mol-
ecules generate a Th1 response, while mutant variants that bind
weakly to MHC class II generate a Th2-dominated response (17),
suggesting that cognate ligand density may also regulate the Th1/
Th2 choice.
Scavenger receptors (SRs)5 bind to a variety of polyanionic li-
gands and deliver them into the endolysosomal pathway (18), and
their expression levels are not altered by ligand binding (19, 20).
They were initially thought to be present uniquely on cells of the
monocytic lineage, although the more recently defined class B SRs
and related receptors are found on B cells as well (21). Many
proteins are known to become SR ligands when chemically mod-
ified to enhance their negative charge by alteration of the e amino
groups of their lysine residues with acetic or maleic anhydrides, or
more physiologically, malondialdehyde (22). We have shown pre-
viously that maleylating protein immunogens so that they become
SR ligands leads to better presentation to T cells in vitro and to
greater immune responses in vivo (23). We have now investigated
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whether there is also a shift in the Th1/Th2 balance generated by
maleylated Ags, and we have gone on to examine if alteration of
costimulatory capabilities, dominance of APC lineages, and/or
cognate signal modulation is likely to be responsible for the quan-
titative and qualitative modulation of the immune response by
these SR-targeted Ags.
Materials and Methods
Mice
BALB/c and C3H/HeJ mice (The Jackson Laboratory, Bar Harbor, ME),
bred in the Small Animal Facility of the National Institute of Immunology,
New Delhi, India were used in all experiments. Mice were immunized i.p.
with varying weekly doses of Ag, either in PBS or with alum (Alhydrogel,
Superfos, Vedback, Denmark) for 1 to 3 wk and used 4 to 6 days after the
last dose. They were bled from the retro-orbital venous plexus under in-
halation anesthesia and sera separated for Ab assays. For measurement of
T cell responses, mice were killed by cervical dislocation, spleens were
dissected, and single cell suspensions were prepared for use. Group sizes of
five to eight mice each were used for the serologic experiments, while two
to three mice each were used for the T cell proliferation and cytokine
analysis experiments.
Chemical modification of proteins
BSA (Sigma, St. Louis, MO), diphtheria toxoid (DT) (Serum Institute,
Pune, India), tetanus toxoid (TT) (Serum Institute), and chicken conalbu-
min (CA) (Sigma) were maleylated at alkaline pH as described earlier (23).
The maleylated proteins were subjected to extensive dialysis against PBS,
and the degree of maleylation was estimated from the loss of active e
-amino groups (24). Only proteins with over 90% substitution were used
for experiments.
Ag-specific Ab assays
Polyvinyl chloride microtiter plates (Falcon, Becton Dickinson Labware,
Franklin Lakes, NJ) were coated with the appropriate Ag (10 mg/ml). Abs
in immune sera were detected in enzyme immunoassays (EIAs) using goat-
anti mouse Ig peroxidase followed by o-phenylenediamine (Sigma) and
H2O2. Concentrations were calculated on the basis of standard curves of
affinity-purified mouse Ig run in parallel EIAs. Ag-specific IgG1 and IgG2a
levels were determined by using goat anti-mouse isotype-specific Abs (Sig-
ma) for IgG1 and IgG2a and rabbit anti-goat Ig peroxidase for detection.
Reciprocal log titers of Ag-specific IgG1 and IgG2a levels were estimated
for calculating IgG1:IgG2a ratios.
T cell activation assays
Spleen cells from immune mice were cultured with graded doses of Ags in
96-well flat-bottom microtiter plates (Corning Glass, Corning, NY) at 2 to
3 3 106 cells/ml in 200 ml of L-glutamine-fortified Click’s EHAA medium
(Irvine Scientific, Irvine, CA) containing 5 3 1025 M 2-ME (Life Tech-
nologies, Grand Island, NY), antibiotics, and 10% FCS (Hyclone, Logan,
UT). The wells were pulsed with 0.5 to 1.0 mCi of [3H]thymidine (Am-
ersham, Amersham, U.K.) for 12 to 16 h in an 84- to 100-h assay, and
harvested onto glass fiber filters for scintillation counting (Betaplate; Wal-
lac, Finland). Data are expressed as mean cpm of triplicate cultures. SEM
were less than 20% of the mean values. For cytokine analyses, spleen cells
from immune mice were cultured in parallel with graded doses of Ag at
5 3 106 cells/ml as above. At 48 to 72 h, culture supernatants were col-
lected, freeze-thawed, and assayed for IL-4, IL-10, and IFN-g using EIAs.
In order to examine the ability of SR ligands to modify costimulatory
abilities of APCs for naive T cells, plastic-adherent peritoneal cells were
cultured in the presence or absence of 100 mg/ml maleyl-BSA. After 36 to
40 h, the cells were harvested, washed, and graded numbers of these cells
were used as APCs with or without the further addition of 100 mg/ml of
maleyl-BSA as an SR ligand during T cell stimulation. They were cultured
at various doses with normal syngeneic thymocytes (2.5 3 106/ml) and
anti-CD3-e Ab (500-A2 (25); gift of Dr. C. A. Janeway, Yale University,
New Haven, CT) as a 1:10 dilution of culture supernatant. After 48 h of
incubation, plates were pulsed with 0.5 mCi/well of [3H]thymidine for 12 h,
harvested, and counted as above.
The T cell clone D10.G4.1 (26), which recognizes peptide 134-146
from chicken conalbumin on I-Ak (27), was maintained by stimulation with
irradiated H-2k (C3H/HeJ) spleen cell APCs and 100 mg/ml of conalbumin
at 7- to 10-day intervals. For use, D10.G4.1 cells were separated from
residual APCs 10 to 15 days after restimulation by density centrifugation
(lympholyte M; Cedarlane, Hornby, Ontario, Canada). Such D10.G4.1
cells did not show any proliferation when Ag or APCs were added alone
without the other, and were used at 1 3 105/ml in assays along with vary-
ing numbers of irradiated or paraformaldehyde-fixed APCs and varying
doses of Ags as shown. Cultures were pulsed with [3H]thymidine 36 h later
for 12 h, harvested, and counted as above.
For uptake and subsequent presentation of CA and maleyl-CA, C3H/
HeJ dendritic cells (DCs) (1.5 3 104/ml), plastic-adherent peritoneal cells
(3–5 3 105/ml) or plastic adherence-depleted spleen cells (5 3 105/ml)
were cultured with titrated Ag doses and 105/ml D10.G4.1 cells. These
assays were also set up with and without 300 mg/ml of maleyl-BSA in
order to examine the effects of a “cold” SR ligand on the presentation of
native and maleyl-CA.
For estimating the relative peptide-MHC ligand densities generated in
vivo by native vs maleylated Ags, native or maleylated CA (1 mg/mouse)
was injected i.p. in PBS at various times prior to sacrifice. Spleen cells
from these mice were fixed with 1% paraformaldehyde (Sigma) in PBS for
45 s at ambient temperature, washed extensively with PBS to remove ex-
cess paraformaldehyde, and graded numbers of such fixed spleen cells were
used to stimulate 1 3 105 cells/ml of D10.G4.1 in 96-well plates as above.
Cytokine analyses
EIAs were done on culture supernatants using appropriate purified and
biotinylated Ab pairs for IL-4, IFN-g, IL-12 (Genzyme, Boston, MA), and
IL-10 (PharMingen, San Diego, CA). Purified anti-mouse IL-4/IFN-g/IL-
10/IL-12 mAbs were adsorbed for capture on polystyrene microtiter plates
(Nunc, Roskilde, Denmark). The culture supernatants were followed by
biotinylated anti-mouse IL-4/IFN-g/IL-12/IL-10. Streptavidin-peroxidase
(Genzyme), followed by hydrogen peroxide and tetramethylbenzidine (Sig-
ma) were used for detection. Titration curves of rIL-4, IFN-g, IL-12 (Gen-
zyme), and IL-10 (PharMingen) were used as standards for calculating
cytokine concentrations in the culture supernatants tested. The limits of
detection for IL-4 were routinely in the range of 5 to 15 pg/ml, and for
IFN-g, IL-10, and IL-12 in the range of 15 to 30 pg/ml.
Preparation of cellular subpopulations
Splenic adherence-depleted cells were prepared from C3H/HeJ mice by
plastic adherence for 1 h. Peritoneal adherent cells were prepared from
C3H/HeJ mice by taking the plastic-adherent fraction of peritoneal exudate
cells (PECs) from thioglycollate broth-primed C3H/HeJ mice after 1 h of
adherence. Peritoneal cells similarly harvested from mice not primed with
thioglycollate broth are referred to as peritoneal washout cells.
For preparing splenic DCs for functional assays, a method described
previously was used with minor modifications (28). Briefly, low density
splenic cells isolated on a Percoll gradient (40–50% interface) were ad-
hered to plastic and the nonadherent cells discarded. The weakly adherent
cells were then passed through a column of glass beads coated with mouse
Ig-anti-Ig immune complexes to remove FcR-bearing macrophages.
In order to obtain partially purified DC-enriched splenic cells in suffi-
cient numbers for flow cytometric analyses, plastic-adherent splenic cells
were cultured overnight in the presence of 5 ng/ml granulocyte-macro-
phage-CSF (Peprotech, Rocky Hills, NJ), the weakly adherent cells were
loaded on a Percoll density gradient, and the cells from the 40 to 50%
interface were used as a DC-enriched population.
Flow cytometry
For flow cytometry, cells (1 3 105 to 1 3 106/well) were incubated with
the primary staining reagents in 50 ml for 45 min on ice. Heat-aggregated
rabbit serum was used at 1% in the staining buffer (PBS containing 0.1%
NaN3 and 2% FCS) to block FcRs. After washing in staining buffer, similar
incubations were used for secondary and tertiary reagents as needed.
Stained cells were fixed in 0.2% paraformaldehyde and stored at 4°C until
analyzed. Samples were analyzed on a Bryte-HS flow cytometer (Bio-Rad,
Hemel Hampstead, U.K.), and data analysis was carried out using WinMDI
shareware.
Monoclonal antibodies for CD11a/CD18 (M17/4.2, TIB217, American
Type Culture Collection (ATCC); CD11b/CD18 (M1/70.16, TIB128,
ATCC); and CD54 (YN/1.7.4, CRL 1878, ATCC) were used as culture
supernatants and were detected by using donkey anti-rat IgG-phycoerythrin
(PE) (Jackson ImmunoResearch, West Grove, PA). CD40 and CD86 were
detected by using fluorescein-coupled Abs (PharMingen), while CD80 was
detected by using anti-CD80-PE (PharMingen). mAbs for MHC class I
(34-4-20S; HB75; (ATCC), and MHC class II (212.A1) (29) were used as
culture supernatants and were detected by using biotinylated rabbit anti-
mouse IgG(Fc) (Jackson ImmunoResearch) followed by avidin-fluorescein
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(Vector, Burlingame, CA). The binding of the mAb to heat-stable Ag
(CD24) (J11d.2; TIB183; ATCC) was detected by biotinylated anti-murine
IgM (Jackson ImmunoResearch) followed by avidin-fluorescein.
Anti-maleyl-protein antisera were generated by immunizing Wistar rats
with 100 mg of maleyl-CA in CFA (Difco, Detroit, MI). Three weeks later,
they were boosted with 100 mg maleyl-CA in IFA (Difco) and bled from
the retro-orbital plexus under inhalation anesthesia 1 wk later. As we have
demonstrated previously, most maleyl-proteins are serologically cross-re-
active with each other (23), and thus these rat anti-maleyl-CA antisera bind
well to maleyl-BSA (data not shown). Pooled sera were used for detection
of cell-bound maleyl-BSA in flow cytometric assays. SR binding on cells
was detected by maleyl-BSA at 25 mg/ml, followed by this rat anti-maleyl-
protein antiserum at a 1:200 dilution, and revealed by species-specific poly-
clonal donkey anti-rat IgG-PE (Jackson ImmunoResearch). A culture su-
pernatant containing the hamster mAb N418 (HB 224; ATCC; kind gift of
Prof. C. A. Janeway, Yale University, New Haven, CT) recognizing mouse
DCs (30) was used to identify splenic DCs, and binding was detected by a
polyclonal species-specific anti-hamster IgG-fluorescein (Jackson Immu-
noResearch). Anti-mouse IgM-fluorescein (Jackson ImmunoResearch) was
used to stain B cells, while a monoclonal hamster anti-mouse CD3-e (500-
A2) followed by anti-hamster IgG-fluorescein (Jackson ImmunoResearch)
was used to detect T cells.
Results
Effect of maleylation of immunogen on immune T cell cytokine
profiles
BALB/c mice were immunized with 100 mg of either DT or ma-
leyl-DT in PBS i.p. at weekly intervals for 2 or 3 wk, and splenic
T cell stimulation assays were set up with graded doses of ma-
leyl-DT or DT 4 or 5 days after the last dose. Culture supernatants
were collected 72 h later and analyzed for the presence of IFN-g,
IL-4, and IL-10. Maleyl-DT-immune cells clearly make more
IFN-g and less IL-4 and IL-10 than DT-immune cells do in re-
sponse to maleyl-DT (Fig. 1, A, B, and C). This relative dominance
of IFN-g in maleyl-DT-immune mice does not depend on delivery
of Ag to SRs during recall in vitro, since using DT instead of
maleyl-DT gives similar results (Fig. 1, D, E, and F). The results
of the proliferation assay on these samples (Fig. 1G) confirm that,
as we have shown earlier (23), maleyl-DT-immune mice show
higher responses to both forms of DT and that maleyl-DT recalls
responses better than DT does in both groups of mice.
To ensure that this shift to an IFN-g-dominated response in-
duced by maleylation of Ag was not peculiar to DT, C3H/HeJ mice
were immunized with either CA or maleyl-CA (single dose of 1
mg/mouse i.p. in PBS), their spleen cells were stimulated 10 days
later with either Ag in vitro, and IL-4, IL-10, and IFN-g were
assayed in the culture supernatants. Again, maleyl-Ca-immune
mice generate more IFN-g as compared with IL-4 or IL-10 than
CA-immune mice do whether CA or maleyl-CA is used as the
recall Ag in vitro (Fig. 2).
Modulation of Ag-specific IgG1:IgG2a ratios in vivo by maleyl-
protein immunization
In order to examine if the cytokine differences seen in culture were
also reflected in immune responses in vivo, we analyzed the bal-
ance between the IL-4-dependent isotype IgG1 (31, 32) and the
IFN-g-dependent isotype IgG2a (33) in serum Abs in immunized
mice. Maleylated and native Ags show no B cell cross-reactivity
but demonstrate significant T cell cross-reactivity (23). We have
therefore done “cross-priming” experiments, in which the first im-
munization or “priming” is with either DT or maleyl-DT as three
weekly doses of 100 mg each i.p., followed by the administration
of native Ag in PBS for cross-priming 1 wk after the last priming
dose. Serum Abs against various Ags were estimated 1 wk after the
cross-priming. While the T cell cross-reactivity between native and
maleyl-DT (23) (Fig. 1) permits generation of anti-DT Abs upon
FIGURE 1. Immunization with maleyl-DT results in a relatively more
Th1-dominant response than immunization with DT does. A and D show
the IFN-g levels, B and E show the IL-4 levels, and C and F show the IL-10
levels in stimulated spleen cell culture supernatants, while G shows the
proliferation of stimulated spleen cells of mice immunized as shown in the
key (immunogen/recall Ag). The experiment shown is representative of
three independent experiments.
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initial priming with maleyl-DT-PBS, priming by DT-PBS did not
generate detectable levels of serum Abs (data not shown), and
therefore the IgG1:IgG2a ratios could not be compared. We there-
fore used alum as an adjuvant for the priming Ags. Mice were thus
immunized i.p. with either DT-alum or maleyl-DT-alum. The
cross-priming Ag was 100 mg DT-PBS, and mice were bled for
determining serum Ab levels a week after the cross-priming dose.
The IgG1:IgG2a ratio in serum anti-DT Abs after priming with
DT-alum is significantly higher than in that following maleyl-DT-
alum priming (Fig. 3). A similar modulation of the IgG1:IgG2a
ratios can be observed using TT-PBS and maleyl-TT-PBS for
priming, where the ratios can be compared without the need to
invoke the help of alum as an adjuvant since TT-PBS triggers
significant levels of serum anti-TT Abs (Fig. 3). These data sup-
port the probability that maleyl-immunogens skew the T cell re-
sponse in favor of IFN-g in vivo.
Effect of maleyl-protein on levels of macrophage costimulatory
molecules
One possibility to explain this shift in the Th1/Th2 balance by
maleyl-immunogens is the modification of costimulatory proper-
ties of SR-bearing APCs by SR ligation via the maleyl-protein Ag.
In order to begin examining if SR ligation could alter the costimu-
latory signaling capabilities of SR-bearing APCs, adherent PECs
treated with maleyl-BSA were stained for various cell surface mol-
ecules involved in delivery of accessory signals to T cells. At 24,
48, and 72 h of incubation with various stimuli, adherent PECs
were stained for MHC class I, MHC class II, CD11b/CD18,
CD11a/CD18, CD54, CD24, CD40, CD80, and CD86. As Figure
4 shows, even by 72 h, there are no significant differences induced
by maleyl-BSA (500 mg/ml) in the expression levels of any of
these molecules. However, cells treated with LPS (25 mg/ml;
FIGURE 2. Immunization with maleyl-CA results in a relatively more Th1-dominant response than immunization with CA does. A and D show the
IFN-g levels, B and E show the IL-4 levels, and C and F show the IL-10 levels in culture supernatants from stimulated spleen cells of mice immunized
as shown in the key (immunogen/recall Ag). The experiment shown is representative of five independent experiments.
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Sigma) show higher levels of CD24, CD54, CD80, and CD86,
while those treated with IFN-g (0.3 mg/ml; Genzyme) show in-
creases in the levels of MHC class II, CD54, and CD86. Results at
24 and 48 h of incubation were similar (data not shown). Thus,
none of the membrane-associated molecules involved in T cell-
APC adhesion or costimulation that we have examined show any
alteration in their expression upon SR ligation.
Since IL-12 has been shown to be critically involved in some
instances of a preferential bias of the immune response toward Th1
cytokine production (6, 11, 13), we tested whether maleylated pro-
teins could induce IL-12 production from macrophages. Adherent
PECs were titrated at various doses from 3 3 106/ml to 3 3 103/ml
in the presence or absence of 100 mg/ml of BSA, maleyl-BSA, or
50 mg/ml of polyinosinic-polycytidylic acid (poly(I:C)), or 10
ng/ml of IFN-g, incubated at 37°C for 24 to 48 h, and the culture
supernatants tested for the presence of IL-12 using the EIA as
described. As shown in Figure 5, both poly(I:C) and IFN-g in-
duced IL-12 secretion from macrophages, while maleyl-BSA was
unable to do so.
Inability of SR ligation to enhance T cell activation by
macrophages
In addition to looking at the levels of costimulatory molecules on
APCs stimulated with a maleyl protein, we also investigated the
costimulatory properties of such APCs in a functional assay.
D10.G4.1 cells were stimulated with titrated doses of CA or ma-
leyl-CA in the presence or absence of 300 mg/ml maleyl-BSA as
a potential inducer of costimulation. The results (Fig. 6A) show
that maleyl-BSA does not cause any increment in the response of
D10.G4.1 to CA, and that it decreases the response to maleyl-CA
down to levels comparable with that to CA. Thus, unless the spe-
cific Ag is delivered through the SRs, there is no enhancement of
the T cell response.
However, since the modulation we observe as a result of protein
maleylation is in the immunogenicity, we also needed to test a
FIGURE 3. IgG1:IgG2a ratios in serum Abs depend on whether native
or maleyl-Ag is used for priming. IgG1:IgG2a ratios in serum anti-DT
(open bars) or anti-TT (hatched bars) Abs of various groups of mice (5–6
mice per group) are shown as mean 6 SE. The immunization protocol for
each group is shown as priming Ag/cross-priming Ag. The data are rep-
resentative of three independent experiments.
FIGURE 4. Ligation of SRs on macrophages does not cause any sig-
nificant change in cell surface levels of the various molecules indicated.
Flow cytometric analyses of adherent PECs cultured for 72 h in either
medium alone, or LPS (25 mg/ml), or IFN-g (0.3 mg/ml), or maleyl-BSA
(500 mg/ml) and stained for the detection of various molecules are shown
as mean fluorescence intensity data. The data shown are representative of
three independent experiments.
FIGURE 5. Maleyl-BSA does not induce the production of IL-12 from
macrophages. C3H/HeJ-adherent PECs were incubated at various cell con-
centrations as shown with either 100 mg/ml BSA, 100 mg/ml maleyl-BSA,
50 mg/ml poly(I:C), or 10 ng/ml IFN-g. Culture supernatants were assayed
for IL-12 after 48 h. The experiment shown is representative of four in-
dependent experiments.
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source of truly naive T cells so that the effects of the addition of a
maleyl protein on the costimulatory properties of APCs could be
examined in relevant fashion. We therefore used thymocytes as a
source of predominantly naive T cells capable of responding to
anti-CD3, and adherent peritoneal washout cells as a source of
SR-bearing macrophages that would cross-link the anti-CD3 Ab
via FcRs in addition to providing costimulation. Adherent perito-
neal cells were cultured with or without maleyl-BSA for 40 h and
then titrated as APCs for anti-CD3-mediated proliferation of syn-
geneic thymocytes, again in either the presence or absence of ma-
leyl-BSA. It can be seen that the proliferation of thymocytes is not
dramatically different whether or not maleyl-BSA is present, either
as a prior stimulator of macrophages or during the T cell stimu-
lation assay (Fig. 6B), suggesting that maleyl-BSA does not mod-
ify any costimulatory functions critically enough to change the
resultant T cell activation achieved. Thus, maleyl proteins do not
FIGURE 6. Engagement of SRs on macrophages does not alter their
costimulatory capacities for T cell activation significantly. A shows the
proliferation of D10.G4.1 cells stimulated with peritoneal APCs and ti-
trated doses of CA or maleyl-CA in the presence or absence of 300 mg/ml
of maleyl-BSA. The experiment shown is representative of three indepen-
dent experiments. B shows the proliferation of thymocytes stimulated with
anti-CD3 Ab and various doses of syngeneic adherent peritoneal cells
treated with maleyl-BSA as shown (prior treatment/treatment during T cell
assay). The experiment shown is representative of four independent
experiments.
FIGURE 7. Like PECs, DCs present maleyl-protein better, and this pre-
sentation is blocked by an SR ligand. D10.G4.1 cells were stimulated with
varying doses of either CA or maleyl-CA in the presence or absence of 300
mg/ml maleyl-BSA as shown. Adherent PECs as APCs were used in A and
splenic DCs in B. The data are representative of three independent
experiments.
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cause any significant alteration in any of the costimulatory prop-
erties of macrophages that we have investigated.
Presentation of maleyl-CA by DCs
Since APC choice has been suggested to be a major factor in de-
termining the Th1/Th2 balance in the immune responses generated
(8, 10), it became necessary to test whether the other major “pro-
fessional” APC types, DCs and B cells, could also bind and present
maleyl-protein.
Splenic DCs were tested in comparison with peritoneal adherent
cells for the ability to present maleyl-CA and CA to the CA-spe-
cific T cell clone D10.G4.1. Both the peritoneal macrophages and
the splenic DCs present maleyl-CA better than CA to D10.G4.1
(Fig. 7). The ability of splenic DCs to present maleyl-CA to
D10.G4.1 was over 1000-fold better than for CA, similar to the
ability of adherent PECs. Addition of an excess of maleyl-BSA in
this assay does not affect the presentation of CA by either APC
population at all, but it inhibits the presentation of maleyl-CA so
that there is no longer any distinction between the presentation of
maleyl-CA and CA (Fig. 7).
In order to ensure that possible contamination of these DC prep-
arations by non-DC cells was not responsible for enhanced pre-
sentation of maleyl-CA, we next directly stained DC-enriched
C3H/HeJ spleen cells in a two-color flow cytometric analysis for
FIGURE 8. Some DCs bind to maleyl-BSA. Splenic low-density cells were stained in a two-color flow cytometric analysis with the anti-DC Ab N418
and maleyl-BSA. A shows the staining of these cells with N418 (thick line) over a control (thin line). B shows the staining of the N418-negative cells in
A (unbroken arrow) with maleyl-BSA (thick line) or BSA (broken line) over a control (thin line). C shows the staining of the N418-binding cells in A
(broken arrow) with maleyl-BSA (thick line) or BSA (broken line) over a control (thin line). D shows the staining of the total cell population with
maleyl-BSA (thick line) or BSA (broken line) over a control (thin line). E shows the staining of the maleyl-BSA-negative cells in D (unbroken arrow) with
N418 (thick line) over a control (thin line). F shows the staining of the maleyl-BSA-positive cells in A (broken arrow) with N418 (thick line) over a control
(thin line). The data are representative of two independent experiments.
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the ability of DCs to bind maleyl-proteins. Splenic DCs were de-
tected by a DC-specific mAb, N418, and were tested for the bind-
ing of maleyl-BSA. These DC-enriched splenic cells show the
presence of N418-binding DCs (Fig. 8A). When the N418-negative
cells (shown by the solid arrow in Fig. 8A) are gated and analyzed,
they show excellent staining with maleyl-BSA (Fig. 8B) as ex-
pected, since most of them are likely to be macrophages. Some of
the N418-positive cells (from the gate shown by the interrupted
arrow in Fig. 8A) also stain very well with maleyl-BSA (Fig. 8C),
suggesting that at least some DCs can bind to SR ligands. Figure
8D shows the staining of the total DC-enriched population with
maleyl-BSA. Figure 8E shows the staining of maleyl-BSA-dull
cells (in the gate indicated by the solid arrow in Fig. 8D) with
N418, while Figure 8F shows the staining of maleyl-BSA-bright
cells (as gated in Fig. 8D by the interrupted arrow) with N418,
establishing that a significant proportion of maleyl-BSA-binding
cells bind N418 and are therefore DCs. These staining data, to-
gether with the earlier functional findings, show that enhanced
presentation of maleyl-CA over CA by DCs occurs through recep-
tor-mediated uptake of maleyl-CA.
Presentation of maleyl-CA by B cells
Although maleyl-BSA is indeed a ligand for class A SRs, it is also
known to bind to other cell surface molecules such as the class B
SRs and related receptors, some of which can be found on B cells
FIGURE 9. Splenic B cells bind to maleyl-BSA although T cells do not.
Two-color flow cytometric analysis of plastic nonadherent spleen cells is
shown for binding of maleyl-BSA vs either anti-IgM (A), or anti-CD3-e
(B). The data are representative of two independent experiments.
FIGURE 10. B cells present maleyl-CA better than CA, and this pre-
sentation is blocked by a SR ligand. Proliferative responses of D10.G4.1 to
varying doses of CA or maleyl-CA either in the presence or absence of 500
mg/ml of maleyl-BSA are shown. The APCs used were either total spleen
cells (A), or macrophage- and DC-depleted spleen cells (B) from C3H/HeJ
mice. The data are representative of three independent experiments.
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(21). Two-color flow cytometric analysis of plastic nonadherent
splenic cells from C3H/HeJ mice shows that maleyl-BSA binds
well to IgM-bearing B cells but not to CD3-e-bearing T cells (Fig.
9). In order to examine if this binding results in any improvement
of presentation of maleylated protein over its native counterpart by
B cells, splenic cells were depleted of macrophages and DCs by
extensive plastic adherence until neither CD11b-bearing cells
(macrophages) nor N418-binding cells (DCs) could be detected
any longer by flow cytometry (data not shown). Such macrophage-
and-DC-depleted cell preparations could still present maleyl-CA
about 100- to 300-fold better than CA to D10.G4.1 cells, and this
enhanced presentation was blocked by the presence of competing
maleyl-BSA (Fig. 10). Thus B cells also take up a maleyl-protein
in receptor-mediated fashion and present it with greater efficiency
than its non-maleylated counterpart. Maleyl-proteins therefore
make no distinctions between the APC lineages through which
they are presented to T cells.
Effect of Ag maleylation on T cell ligand densities generated
in vivo
Another factor in the development of a T cell response dominated
by IFN-g is the possibility of higher densities of peptide-MHC
ligands generated in situations in which such a dominance is seen
(17). To test whether such a possibility could be invoked in our
experimental system, we have attempted to compare the ligand
levels generated on APCs in vivo after immunization with either
native or maleyl-CA.
C3H/HeJ mice were given 1 mg each of maleyl-CA or CA in
PBS i.p. (as used in the experiment in Fig. 2) to look at the kinetics
of appearance of specific CA peptide-MHC complexes on their
splenic APCs by following the stimulatory capacity of the spleen
cells for D10.G4.1 over a 4-day period post-Ag injection. Splenic
cells were fixed with paraformaldehyde to inhibit any further Ag
processing in vitro (34, 35). Figure 11A shows that the fixation
protocol used does not permit any Ag processing to take place in
vitro, since intact CA can no longer be processed by such fixed
spleen cells from mice not given Ag. When spleen cells from mice
given native or maleyl-CA 4 to 94 h earlier are tested, the maximal
T cell stimulation, reflecting maximal availability of peptide-MHC
complexes, occurs 4 h after immunization in the CA-treated group
(Fig. 11B). From 13 h onward, the T cell response to splenic APCs
from such CA-treated mice is practically undetectable. Spleen cells
from mice given maleyl-CA also stimulate D10.G4.1 maximally as
early as 4 h after injection; however, T cell stimulation remains
comparable at 13 h, and although a decline is seen by 22 h, stim-
ulation is detectable up to 70 h (Fig. 11C). No T cell stimulation
is detected 94 h after injection of Ag in either group, but T cell
FIGURE 11. Peptide-MHC complex density
declines differentially over time on spleen cells of
mice given CA or maleyl-CA. A shows the pro-
liferative response of D10.G4.1 cells to varying
doses of CA presented by either unfixed gamma-
irradiated (2000 rad) or fixed C3H/HeJ spleen
cells (1.5 3 106 cells/ml). B and C show the re-
sponses of D10.G4.1 to varying doses of fixed
spleen cells from mice previously injected with
CA (B) or maleyl-CA (C) at the times shown.
These data from B and C have been replotted in D
to show responses of D10.G4.1 over a period of
time to fixed spleen cells (1.5 3 106 cells/ml)
from mice given either CA or maleyl-CA. The ex-
periment shown is representative of four indepen-
dent experiments.
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stimulation is greater with APCs from maleyl-CA-treated mice at
all other time points (Fig. 11D).
Discussion
We have previously shown that immunization with maleyl-DT in
PBS generates a better T cell proliferative response than does DT-
PBS (23), indicating enhanced immunogenicity. We have now ex-
amined the possibility that immunization with maleyl-proteins
may also modulate the cytokine profiles of the T cells triggered, by
analyzing the cytokine secretion profiles of T cells primed with
either native or maleyl-DT without adjuvant. Maleyl-DT-immune
cells produce more IFN-g than DT-immune T cells do when cul-
tured in vitro either with DT or maleyl-DT, indicating that the
recall Ag has little role in determining the cytokine response
mounted (Fig. 1). This is not an isolated finding with just one Ag,
since the findings are reproducible with CA/maleyl-CA (Fig. 2),
and with yet another protein—OVA and maleyl-OVA (data not
shown). These are not simply cytokine differences seen in the re-
call responses in vitro, since Abs generated in vivo using maleyl-
proteins also show a relative dominance of the IFN-g-dependent
IgG2a isotype over the IL-4-dependent IgG1 isotype as compared
with the Abs generated by native Ag priming (Fig. 3). Time course
kinetics of the IFN-g and IL-10 production in vitro show that the
maximum level of these cytokines was reached in the culture su-
pernatants between 72 and 96 h for both maleyl-CA-immune and
CA-immune T cells (data not shown).
What is the basis of the observed differences (quantitative as
well as qualitative) in the immune responses to maleylated Ags?
Enhancement and modulation of T cell immunogenicity may be
mediated through either cognate or costimulatory signals from
APCs, and therefore we have tried to examine the effects of ma-
leyl-proteins on both signals.
Macrophage SR ligation has already been reported to lead to
phosphatidylinositol-4,5-biphosphate (PIP2) hydrolysis, NF-kB in-
duction, and TNF-a transcription in macrophages (36). It also in-
duces the secretion of PGE2 and IL-1 (37, 38), both of which have
significant effects on T cell activation (39, 40). It is thus possible
that ligation of SRs on such receptor-bearing APCs may lead to
modifications in the costimulatory functions of these APCs, and
such costimulation-associated changes may also affect the outcome
of the resultant T cell priming. Thus, it was of interest to examine
the outcome of SR ligation on costimulatory properties. One way
to do this is to examine the levels of expression of various mem-
brane molecules found to be important in adhesion and/or costimu-
latory signaling on SR-stimulated APCs. We have looked for mod-
ulation in the levels of CD11b/CD18, CD11a/CD18, CD54, CD24,
CD40, CD80, and CD86, as well as in MHC class I and MHC class
II, and we find no change in these levels on adherent PECs upon
SR ligation (Fig. 4). Neither does maleyl-BSA induce any produc-
tion of IL-12 from PECs (Fig. 5), in concordance with a recent
report, which in fact shows that maleyl-BSA suppresses the in-
duction of IL-12 production by bacterial LPS (41). Thus, neither of
the two molecular interactions recently claimed to be critical in
determining the Th1/Th2 balance of the resultant T cell commit-
ment, CD80/CD86 (15) and IL-12 (6, 11, 13), is altered by maleyl-
BSA. Maleyl-BSA does not induce the secretion of any IFN-g
from APCs either (data not shown). Thus, if any costimulatory
property relevant to the differential control of Th1/Th2 pathways
was indeed altered by maleyl-proteins, it would be a hitherto
uncharacterized one.
Although the costimulatory signals assayed so far do not show
any differences, the possibility always remains that some other, as
yet unidentified, alterations are in fact altering costimulation. To
address this, we have directly tested the costimulatory properties in
a functional fashion, with enhancement of T cell activation as the
criterion.
We have shown previously that if DT-immune spleen cells are
cultured in vitro with DT, the resultant levels of proliferation
reached are not different either in the presence or absence of 100
mg/ml of maleyl-BSA acting as a SR ligand (23). Clearly, SR-
bearing APCs are present and important in these cell populations,
since the presentation of maleyl-DT is enhanced, and the enhance-
ment is blocked by the addition of maleyl-BSA (23). We have now
also looked at the proliferation of D10.G4.1 cells when CA is
presented in the presence or absence of maleyl-BSA, and no en-
hancement in stimulation can be observed in the presence of the
SR ligand (Fig. 6A). Thus, it appears that SR ligation, by itself,
does not affect the ability of SR-bearing PECs to present an Ag to
secondary T cells if that Ag does not itself bind to the SR.
However, the costimulatory requirements of naive and primed T
cells are significantly different (42–44). It is thus possible that,
while SR ligation has no effects on the costimulation relevant to
secondary T cells, the situation may be different with naive T cells,
and that may contribute to the modulations in immunogenicity we
have reported previously (23) as well as here. Therefore, it was
necessary to test a population of naive T cells for such SR ligation-
mediated modulation of costimulatory functions of APCs indepen-
dent of SR-mediated delivery of Ag. Rather than attempting a
CD45 isoform-based separation of phenotypically “naive” and
“memory” CD4 T cells (42), we have used thymocytes as the
responding population. Although thymocytes are a heterogeneous
population of T lineage cells, the immature CD41CD81 thymo-
cytes do not proliferate in response to anti-CD3, while the mature
“single-positive” CD41/CD81 thymocytes do (45–48). The ma-
ture single-positive thymocytes consist predominantly of naive T
cells, since circulating memory T cell reentry into the adult thymus
is minimal (49, 50). Thus, the thymocytes responding to anti-CD3
by proliferation would be mainly naive mature T cells. We have
used anti-CD3 as a stimulus that is independent of SRs, and have
examined the effects of an SR ligand on presentation of this stim-
ulus to thymocytes by FcR- and SR-bearing peritoneal adherent
cells, mainly macrophages. Our data clearly show that such SR
ligation makes little difference to the proliferative response of thy-
mocytes (Fig. 6B). Thus, SR ligation is unlikely to modify the
costimulatory properties of the relevant APCs to any major degree.
Maleyl-proteins have very short t1/2 in vivo because of SR-
mediated uptake by macrophages (51). They are therefore unlikely
to reach non-receptor-bearing cells to any significant degree. Yet,
they show enhanced immunogenicity in vivo, although DC-medi-
ated Ag presentation is thought to be essential for immunogenicity
(52, 53). It was therefore necessary to explore the possibility that
DCs express SRs, especially since there are also suggestions that
IL-12 from DCs plays a significant role in Th1 commitment (54).
Macrophages and DCs are known to develop from common
myeloid lineage precursors (55), and circulating monocytes can be
induced to differentiate into DCs by certain combinations of cy-
tokines (56). It did not therefore appear implausible that DCs may
express SRs, and in fact, it has been previously reported that fol-
licular DCs in germinal centers of human lymph nodes are recog-
nized by anti-SR Abs (57). Our data show that maleyl-Ags are
indeed presented better to T cells by murine DCs in addition to
macrophages, and that this presentation is significantly inhibited
by maleyl-BSA and is therefore receptor mediated (Fig. 7). We
have also stained splenic low density cells for SRs and the DC-
specific mAb N418 in a two-color analysis, and Fig. 8 shows that
at least some DCs clearly bind well to maleyl-BSA. Somewhat
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more surprisingly, the same is true for B cells—they do bind ma-
leyl-BSA although T cells do not (Fig. 9), and they show some
enhanced presentation of maleyl-CA to D10.G4.1 cells which is
blocked by maleyl-BSA (Fig. 10). Similarly, transformed B cell
lines also bind maleyl-BSA and present maleyl-CA better than CA
to D10.G4.1 (data not shown). These data are consistent with the
fact that molecules of the class B SR family are found on B cells
in addition to cells of the monocytic lineage (21).
So it appears that all the three major MHC class II-bearing APC
populations—macrophages, DCs, and B cells—can present
maleyl-proteins better than their native counterparts due to recep-
tor-mediated uptake. Thus, injected maleyl-Ags are quite probably
delivered efficiently to DCs and B cells as well as to macrophages,
and no selective differences are likely to exist between maleyl-
immunogens and their native counterparts as far as APC choice is
concerned. In fact, selective depletion of macrophages in vivo be-
fore immunization does not alter the cytokine balance generated by
either native or maleyl-immunogens, although it does decrease the
magnitude of the response triggered by the maleyl-immunogen
(data not shown).
Thus, neither costimulatory modification nor preferential pre-
sentation by some APC types appears to be a viable possibility to
explain the altered immunogenicity of maleyl-proteins. It remains
possible that the enhanced T cell immunogenicity of maleylated
proteins is due simply to greater quantities of peptide-MHC com-
plexes becoming available on APC surfaces due to receptor-
mediated delivery, and such comparatively higher ligand availabil-
ity could also account for the relative skewing of T cell responses
toward the Th1 cytokine profile as has been suggested earlier (17).
With this possibility in mind, we have begun examining the rela-
tive ligand levels generated in vivo on splenic APCs in mice ad-
ministered either native or maleyl-proteins. Such relative ligand
levels have been read out using the ability of these APCs to stim-
ulate a monoclonal T cell line, D10.G4.1, specific for CA—a
method that has been used in other systems as well (58, 59). Al-
though this is an indirect measurement of peptide-MHC complex
levels, it appears to be valid since maleyl-CA and CA are equiv-
alently presented to D10.G4.1 cells in vitro if any receptor-medi-
ated delivery of maleyl-CA is blocked by maleyl-BSA (Figs. 7 and
10). Thus, the enhancement of D10.G4.1 stimulation is not due to
Ag-nonspecific effects of SR ligation, nor is it due to altered pro-
cessing of maleyl-CA per se. It is therefore reasonable to assume
that variations in the stimulation of D10.G4.1 under these circum-
stances reflect real differences in ligand “doses.”
Using such a readout system, it can be seen that administration
of maleylated Ags leads to the presentation of higher levels of
stimulatory peptide-MHC complexes than injection of native Ags
does (Fig. 11). We have confirmed that this pattern holds good for
OVA as well, using OVA-specific T cell hybridomas (data not
shown). This finding is consistent with arguments for a major role
of ligand densities in determining the Th1/Th2 balance (17). In
fact, the longer life of the peptide-MHC complexes in vivo may be
more critical than the level available at any one time point. The t1/2
of peptide-MHC complexes generated from native protein in vivo
does not appear to be very long, in keeping with some reports
(60–62) and contrary to other estimates (63, 64). In fact, our data
show that the t1/2 of such complexes generated from a targeted Ag,
which is presumably taken up by receptor-mediated endocytosis
over a short time span, can be considerably longer than those gen-
erated from an Ag taken up more slowly by pinocytic uptake. It is
not clear whether this indicates some differences in the trafficking
of MHC class II molecules loaded with peptide in the two in-
stances, or whether some differences between the processing com-
partments that SR ligation-initiated endosomes and nonspecific pi-
nosomes enter are responsible.
There have been many indications that APC factors are princi-
pally responsible for the differential commitment of T cells to ei-
ther the Th1 or the Th2 cytokine package. APCs may affect effec-
tor T cell commitment either by modulating the density of peptide-
MHC complexes presented (17), and/or by providing differing
combinations of costimulatory signals (10–12, 15, 16). Our data
show that immunization with maleylated proteins tends to generate
a relatively greater dominance of the Th1 response, and further
suggest that, rather than any major modulation of costimulatory
functions, it is the level of ligand availability generated over time
that plays a major role in this differential commitment.
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